丽珠医药(深交所代码:000513;香港联交所代码01513)宣布,公司心血管领域 1 类创新药 H001的 II 期临床试验入组圆满收官。这款直接凝血酶(IIa 因子)口服抑制剂,针对骨科大手术术后静脉血栓栓塞症预防,直击凝血最下游环节,具有起效迅速、安全性高、用药便捷性强等优势。目前,中国该领域尚无同靶点药物上市, H001有望为患者带来治疗新选择。骨科大手术(主要包括人工髋/膝关节置换术、...
Source Link丽珠医药(深交所代码:000513;香港联交所代码01513)宣布,公司心血管领域 1 类创新药 H001的 II 期临床试验入组圆满收官。这款直接凝血酶(IIa 因子)口服抑制剂,针对骨科大手术术后静脉血栓栓塞症预防,直击凝血最下游环节,具有起效迅速、安全性高、用药便捷性强等优势。目前,中国该领域尚无同靶点药物上市, H001有望为患者带来治疗新选择。骨科大手术(主要包括人工髋/膝关节置换术、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.